| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02142192 2014-000917-30 Details | 2016-09-29 Interventional | 2 | 2 | Natalizumab Multiple Sclero… Sclerosis Relapsing Multi… | Sponsor's decision. - | |||
| NCT02000375 2012-003510-13 Details | 2016-09-29 Interventional | 2 | 20 | Dehydroepiandro… Breast Neoplasm… Neoplasms Androgen Recept… Estrogen Recept… Estrogen Recept… Metastatic Brea… Progesterone Re… Progesterone Re… | Due to slow recruitment and recent new published data - | |||
| NCT00781326 Details | 2016-09-29 Interventional | 4 | 9 | Nimodipine Depression Depressive Diso… | Final cost of study medication was significantly greater than initial estimate, Study was terminated for administrative reasons at the end of Phase I (open label antidepressant treatment). No subjects entered Phase II (Nimodipine vs Placebo). | |||
| NCT02172001 Details | 2016-09-28 Interventional | 3 | 0 | Iron isomaltosi… Anemia Anemia, Iron-De… Deficiency Dise… Iron Deficienci… Iron Deficiency… | Study design not adequate - | |||
| NCT02862145 Details | 2016-09-27 Interventional | 1/2 | 0 | Dexamethasone Melanoma | 5 immune related serious adverse events in Phase 1 study - | |||
| NCT02123498 Details | 2016-09-26 Interventional | 4 | 0 | Omeprazole Pantoprazole Ranitidine Ranitidine bism… Gastroesophagea… Laryngopharynge… Eustachian Tube… | IRB not approved - | |||
| NCT01724918 Details | 2016-09-26 Interventional | 2 | 72 | Lacosamide Epilepsies, Par… Epilepsy Focal Epilepsy | Time limitation for recruitment exceeded. 72 of 90 estimated sample recruited. - | |||
| NCT00281931 Details | 2016-09-26 Interventional | 2 | - | Cyclophosphamid… Fludarabine Fludarabine pho… Rituximab Leukemia Leukemia, Proly… Prolymphocytic … | - - | |||
| NCT02823106 Details | 2016-09-23 Interventional | 1 | 0 | Choline Cytidine Diphos… Verapamil Ischemia Ischemic Stroke | Study put on clinical hold by FDA. Sponsor decided to no pursue the study. - | |||
| NCT00862706 Details | 2016-09-23 Interventional | 4 | 0 | Telbivudine Hepatitis Hepatitis A Hepatitis B Hepatitis B, Ch… Hepatitis, Chro… Compensated Chr… | Stopped with Patients - | |||
| NCT02047747 Details | 2016-09-22 Interventional | 2 | 4 | Dacomitinib Brain Neoplasms Neoplasm Metast… Brain Cancer | slow enrollment - | |||
| NCT00190554 Details | 2016-09-22 Interventional | 3 | - | Cisplatin Fluorouracil Carcinoma Carcinoma, Squa… Esophageal Neop… Esophageal Squa… | - - | |||
| NCT02573935 2014-002187-32 Details | 2016-09-20 Interventional | 2 | 58 | Clarithromycin Multiple Myelom… Neoplasms, Plas… | Suspected side effects to the combination of clarithromycin and VCD (bortezomib,
cyclophosphamide and dexamethasone) - | |||
| NCT00446602 Details | 2016-09-20 Interventional | 2 | 0 | Epoetin Alfa Myelodysplastic… Preleukemia Syndrome Anemia | Due to company decision to focus resources on a larger, controlled study in this patient
population. - | |||
| NCT00336700 Details | 2016-09-19 Interventional | 2 | 25 | Erlotinib Hydro… Gemcitabine Pancreatic Neop… Pancreatic Canc… | Study published November 2010 and no further work will be done - | |||
| NCT02903901 Details | 2016-09-16 Interventional | 4 | 0 | Melatonin Delirium Emergence Delir… | Investigator found that a new study drug that is FDA approved would be superior to melatonin - | |||
| NCT00920153 Details | 2016-09-16 Interventional | 3 | 442 | Bleomycin Carmustine Cytarabine Dacarbazine Dexamethasone Doxorubicin Etoposide Gemcitabine Ifosfamide Liposomal doxor… Melphalan Methylprednisol… Mitoguazone Vincristine Vindesine Vinorelbine Hodgkin Disease Lymphoma | Other new drugs - | |||
| NCT02780830 Details | 2016-09-15 Interventional | 1 | 0 | Ibrutinib Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Core: Relapsed … Module 1: Non-G… | Study D2276C00001 was not started. No patients were enrolled. The sponsor decided to pursue an
alternate design. - | |||
| NCT01986218 Details | 2016-09-15 Interventional | 1 | 36 | BMS-986115 Various Advance… | (Non-safety reason, business objectives have changed) - | |||
| NCT00926627 2007-005117-18 Details | 2016-09-15 Interventional | 2 | 32 | Bosentan Hypertension, P… Sarcoidosis Sarcoidosis, Pu… Pulmonary Hyper… | Not enough patients with the specified criteria could not - |